As part of the arrangement, the Kansas City, Missouri company will share its technology with the university so that it can produce the vaccine for a clinical trial. AC Vaccine is made from a patient's own cancer cells by modifying them with a molecule called a hapten. This process alters the tumor cells and makes them appear foreign to the patient's immune system. When the hapten-modified cells are reinjected in the patient, they stimulate the immune system to recognize the cancer cells and destroy them. AVAX is testing the vaccine in the United States as a treatment for malignant melanoma and for ovarian cancer.
Japan is the top country in the world for direct sales.
The Boca Raton, Florida company has opened a subsidiary in Tokyo and established a Rexall Academy to educate distributors about nutrition, preventative health care and the benefits of Rexall's products.